Inhibition of transcription elongation by the VHL tumor suppressor protein

Germline mutations in the von Hippel-Lindau tumor suppressor gene (VHL) predispose individuals to a variety of tumors, including renal carcinoma, hemangioblastoma of the central nervous system, and pheochromocytoma. Here, a cellular transcription factor, Elongin (SIII), is identified as a functional target of the VHL protein. Elongin (SIII) is a heterotrimer consisting of a transcriptionally active subunit (A) and two regulatory subunits (B and C) that activate transcription elongation by RNA polymerase II. The VHL protein was shown to bind tightly and specifically to the Elongin B and C subunits and to inhibit Elongin (SIII) transcriptional activity in vitro. These findings reveal a potentially important transcriptional regulatory network in which the VHL protein may play a key role.

[1]  L. Hood,et al.  Internal amino acid sequence analysis of proteins separated by one- or two-dimensional gel electrophoresis after in situ protease digestion on nitrocellulose. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[2]  R. Conaway,et al.  RNA polymerase II transcription factor SIII. I. Identification, purification, and properties. , 1993, The Journal of biological chemistry.

[3]  J. Gnarra,et al.  Identification of the von Hippel-Lindau disease tumor suppressor gene. , 1993, Science.

[4]  R. Conaway,et al.  RNA polymerase II transcription factor SIII. II. Functional properties and role in RNA chain elongation. , 1993, The Journal of biological chemistry.

[5]  A. Knudson,et al.  Antioncogenes and human cancer. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[6]  B. Seizinger,et al.  Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma. , 1994, American journal of human genetics.

[7]  William Arbuthnot Sir Lane,et al.  Molecular cloning of an essential subunit of RNA polymerase II elongation factor SIII. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Y Kubota,et al.  Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. , 1994, Cancer research.

[9]  D. Bentley,et al.  Transcriptional elongation by RNA polymerase II is stimulated by transactivators , 1994, Cell.

[10]  R. Conaway,et al.  Transcription : mechanisms and regulation , 1994 .

[11]  R. Conaway,et al.  Roles for both the RAP30 and RAP74 subunits of transcription factor IIF in transcription initiation and elongation by RNA polymerase II. , 1994, The Journal of biological chemistry.

[12]  M. Lerman,et al.  Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. , 1994, Human molecular genetics.

[13]  R. Weinberg,et al.  Tumor suppressor genes. , 1994, Current opinion in genetics & development.

[14]  J. Brooks,et al.  Mutations of the VHL tumour suppressor gene in renal carcinoma , 1994, Nature Genetics.

[15]  A. Kibel,et al.  Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C , 1995, Science.

[16]  B. Seizinger,et al.  Cloning and characterization of a mouse gene with homology to the human von Hippel-Lindau disease tumor suppressor gene: implications for the potential organization of the human von Hippel-Lindau disease gene. , 1995, Cancer research.

[17]  M. Groudine,et al.  Promoter-proximal pausing of RNA polymerase II defines a general rate-limiting step after transcription initiation. , 1995, Genes & development.

[18]  W. Linehan,et al.  Germline mutations in the von Hippel–Lindau disease tumor suppressor gene: Correlations with phenotype , 1995, Human mutation.

[19]  William Arbuthnot Sir Lane,et al.  Elongin (SIII): a multisubunit regulator of elongation by RNA polymerase II , 1995, Science.

[20]  William Arbuthnot Sir Lane,et al.  Positive regulation of general transcription factor SIII by a tailed ubiquitin homolog. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[21]  W. Linehan,et al.  Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. , 1995, JAMA.

[22]  R. Klausner,et al.  Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations. , 1995, Proceedings of the National Academy of Sciences of the United States of America.